Clinical Trial Goal
To find out if the combination of luspatercept and momelotinib is safe and works well to treat transfusion-dependent myelofibrosis
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following diseases:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have received at least 4 units of red blood cell transfusions in the last 2 months. Your doctor can tell you this
- Have not been treated with luspatercept or sotatercept
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Luspatercept is a small molecule inhibitor that blocks TGF-beta in certain cells.
Momelotinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
You’ll get:
Momelotinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
You’ll get:
- Luspatercept – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Momelotinib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
The clinical trial doctors will check your health for up to 6 months.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat transfusion-dependent myelofibrosis is new and unproven.
Contacts
US GSK Clinical Trials Call Center, 877-379-3718, GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, +44 (0) 20 89904466, GSKClinicalSupportHD@gsk.com
Locations
GSK Investigational SiteRECRUITING
Nashville, Tennessee
Contacts:
- US GSK Clinical Trials Call Center, 877-379-3718, GSKClinicalSupportHD@gsk.com
- EU GSK Clinical Trials Call Centre, +44 (0) 20 8990 4466, GSKClinicalSupportHD@gsk.com
Sponsors
lead: GlaxoSmithKline
